FDA approves Skye Bioscience’s IND for glaucoma therapy trial

The US Food and Drug Administration (FDA) has approved Skye Bioscience’s Investigational New Drug (IND) application enabling commencement of SBI-100 Ophthalmic Emulsion (OE) clinical trials.

The clinical trials include a Phase II study to treat primary open angle glaucoma or ocular hypertension (OHT), which is scheduled to begin in the first half of next year.